Background: Poorly differentiated thyroid cancer (PDTC) is a rare but clinically highly
significant entity because it accounts for most fatalities from non-anaplastic follicular cell …

Thyroid cancer comprises different clinical and histological entities. Whereas differentiated
(DTCs) malignancies are sensitive to radioiodine therapy, anaplastic (ATCs) and medullary …

Abstract Objective The BRAF V600E and TERT promoter mutations are well known to be
associated with poor clinical outcomes of papillary thyroid cancer (PTC). Radioactive iodide …

Simple Summary Radioactive iodine treatment is the oldest targeted therapy for
differentiated thyroid cancer. It can be used for normal thyroid remnant ablation (in order to …

Abstract In the upcoming World Health Organization fifth edition classification of endocrine
tumors, there were several major changes related to high grade follicular-derived thyroid …

Poorly differentiated thyroid carcinoma (PDTC) is a rare thyroid carcinoma originating from
follicular epithelial cells. No explicit consensus can be achieved to date due to sparse …

TERT promoter mutations (TERT-p mutations) have been found in many types of cancer and
have emerged to play critical roles in tumor progression. The mutations upregulate TERT …

Background TERT promoter mutations are associated with adverse clinicopathological
characteristics in thyroid carcinomas and considered as a major indicator of poor outcomes …

Poorly differentiated thyroid carcinoma (PDTC) is an aggressive form of follicular cell derived
thyroid carcinoma with a prognosis intermediate between the indolent well differentiated …

Simple Summary In the last decades, many researchers produced promising data
concerning genetics and tumor microenvironment of poorly differentiated thyroid cancer …